BridgeBio to Present New Infigratinib Data in Achondroplasia
PALO ALTO, Calif., September 2, 2026 BridgeBio Pharma, Inc. announced plans to present new clinical data on the impact...
Huntington’s Disease
Advertisement
uniQure Submits BLA for AMT-130 in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, September 2, 2026 uniQure N.V. announced the submission of a Biologics License Application (BLA) to...
Candel Therapeutics Announces Extended Phase 3 Data Presentation at ASTRO 2026
NEEDHAM, Mass., Aug. 3, 2026 Candel Therapeutics, Inc. announced that new data from its Phase 3 clinical program evaluating...
Design Therapeutics Reports RESTORE-FA Progress and Advances GeneTAC® Pipeline
CARLSBAD, Calif., Aug. 3, 2026 Design Therapeutics, Inc. reported second-quarter 2026 financial results while providing key clinical updates across...
Teva Reports Real-World Benefits of AUSTEDO for Huntington’s Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals announced new real-world data demonstrating that treatment with...
Advertisements
Latus Bio Advances Gene Therapy Programs for Rare CNS Diseases
PHILADELPHIA & BOSTON, April 28, 2026 Latus Bio, Inc. has announced new preclinical and computational data supporting its investigational...
VectorY and ShapeTX Partner to Advance AAV5-Based CNS Therapies
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
Advertisement
